Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia.
Established dividend payer with moderate growth potential.
Share Price & News
How has Ryman Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: RYHT.Y exceeded the US Healthcare industry which returned -8.5% over the past year.
Return vs Market: RYHT.Y matched the US Market which returned 5.6% over the past year.
Price Volatility Vs. Market
How volatile is Ryman Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Ryman Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: RYHT.Y ($43.61) is trading above our estimate of fair value ($20.51)
Significantly Undervalued: RYHT.Y is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RYHT.Y is poor value based on its PE Ratio (20.7x) compared to the Healthcare industry average (20.3x).
PE vs Market: RYHT.Y is poor value based on its PE Ratio (20.7x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
Low PEG Ratio: RYHT.Y is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: RYHT.Y is overvalued based on its PB Ratio (3.1x) compared to the US Healthcare industry average (2.5x).
How is Ryman Healthcare forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYHT.Y's forecast earnings growth (14.7% per year) is above the savings rate (2.7%).
Earnings vs Market: RYHT.Y's earnings (14.7% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: RYHT.Y's earnings are forecast to grow, but not significantly.
Revenue vs Market: RYHT.Y's revenue (11.2% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: RYHT.Y's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: RYHT.Y's Return on Equity is forecast to be low in 3 years time (11.7%).
How has Ryman Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: RYHT.Y's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: RYHT.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RYHT.Y had negative earnings growth (-16%) over the past year, making it difficult to compare to the Healthcare industry average (5.3%).
Return on Equity
High ROE: RYHT.Y's Return on Equity (15%) is considered low.
Return on Assets
ROA vs Industry: RYHT.Y's Return on Assets is below or equal to the Healthcare industry average last year.
Return on Capital Employed
ROCE Improving: RYHT.Y's Return on Capital Employed has declined over the past 3 years.
How is Ryman Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: RYHT.Y's short term assets (NZ$353.0M) do not cover its short term liabilities (NZ$550.6M)
Long Term Liabilities: RYHT.Y's short term assets (353.0M) do not cover its long term liabilities (3.9B)
Debt to Equity History and Analysis
Debt Level: RYHT.Y's debt to equity ratio (61.6%) is considered high
Reducing Debt: RYHT.Y's debt to equity ratio has increased from 30.2% to 61.6% over the past 5 years.
Debt Coverage: RYHT.Y's debt is well covered by operating cash flow (30%).
Interest Coverage: RYHT.Y's interest payments on its debt are not well covered by EBIT (3x coverage).
Inventory Level: RYHT.Y has a low level of unsold assets or inventory.
Debt Coverage by Assets: RYHT.Y's debt is not covered by short term assets (assets are 0.3x debt).
What is Ryman Healthcare's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: RYHT.Y's dividend (1.68%) is higher than the bottom 25% of dividend payers in the US market (1.46%).
High Dividend: RYHT.Y's dividend (1.68%) is low compared to the top 25% of dividend payers in the US market (3.76%).
Stable Dividend: RYHT.Y's dividends per share have been stable in the past 10 years.
Growing Dividend: RYHT.Y's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (34.8%), RYHT.Y's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: RYHT.Y's dividends in 3 years are forecast to be covered by earnings (50.7% payout ratio).
What is the CEO of Ryman Healthcare's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Gordon MacLeod 0
Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief ...
CEO Compensation Analysis
Compensation vs. Market: Gordon has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.
Compensation vs Earnings: Gordon's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Management Age and Tenure
Experienced Management: RYHT.Y's management team is considered experienced (2.3 years average tenure).
Board Age and Tenure
Experienced Board: RYHT.Y's board of directors are considered experienced (5.9 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Chief Construction Officer
- Tenure: 0yrs
CEO & Secretary
- Tenure: 2.3yrs
- Compensation: NZ$1.23m
Debbie Versey McClure
Chief Sales & Marketing Officer
- Tenure: 2.8yrs
Chief People & Technology Officer
- Tenure: 0yrs
Chief Financial Officer
- Tenure: 2.3yrs
Independent Chairman of the Board
- Tenure: 20.8yrs
- Compensation: NZ$217.00k
Advisor to the Board
- Tenure: 2.4yrs
- Compensation: NZ$2.73m
- Tenure: 6.8yrs
- Compensation: NZ$136.01k
- Tenure: 8.7yrs
- Compensation: NZ$125.50k
- Tenure: 10.8yrs
- Compensation: NZ$108.00k
- Tenure: 5.1yrs
- Compensation: NZ$136.01k
Anthony Leighs (48yo)
- Tenure: 1yrs
- Compensation: NZ$62.75k
- Tenure: 1.3yrs
- Compensation: NZ$90.83k
Ryman Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Ryman Healthcare Limited
- Ticker: RYHT.Y
- Exchange: OTCPK
- Founded: 1984
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: NZ$6.729b
- Listing Market Cap: NZ$4.218b
- Shares outstanding: 497.74m
- Website: https://www.rymanhealthcare.co.nz
Number of Employees
- Ryman Healthcare Limited
- Airport Business Park
- 92 Russley Road
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RYM||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jun 1999|
|RHCG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1999|
|RH7||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1999|
|RYHT.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Nov 2011|
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/17 00:19|
|End of Day Share Price||2019/09/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.